Mifepristone mediates anti‐proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA1−/2− carriers

@article{PonandaiSrinivasan2019MifepristoneMA,
  title={Mifepristone mediates anti‐proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA1−/2− carriers},
  author={S. Ponandai-Srinivasan and P. G. Lalitkumar and L. Garc{\'i}a and Suby Varghese and J. Carlson and K. Gemzell-Danielsson and A. Floter Radestad},
  journal={Acta Obstetricia et Gynecologica Scandinavica},
  year={2019},
  volume={98},
  pages={250 - 261}
}
  • S. Ponandai-Srinivasan, P. G. Lalitkumar, +4 authors A. Floter Radestad
  • Published 2019
  • Medicine
  • Acta Obstetricia et Gynecologica Scandinavica
  • Women with hereditary mutation in breast cancer‐associated genes (BRCA1−/2−) have a higher lifetime risk of developing ovarian cancer. Here, we aimed to investigate the effect of mifepristone, a selective progesterone receptor modulator of ovarian mesenchymal stem/stromal cells (MSC) from BRCA1−/2− carriers. 
    Precision hormone therapy: gaps and opportunities

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 54 REFERENCES
    Microenvironment and Pathogenesis of Epithelial Ovarian Cancer
    • 65
    • Open Access